The Optical Q HbA1c diagnostic test is a proprietary point-of-care (POCT) fluorescence immunoassay (FIA) designed for prompt and accurate in-vitro quantitative measurement of HbA1c. The Optical Q HbA1c reagent test is the first HbA1c FIA test kit that does not require processing with a centrifuge, allowing for a) quicker results and b) higher accuracy.
Glycated hemoglobin A1c (HbA1c) is a form of hemoglobin that is chemically linked to a sugar. The glycated hemoglobin test measures the concentration of glycated A1c hemoglobin by evaluating the average level of glucose in the blood over the past 2 to 3 months. Hemoglobin is an oxygen-carrying protein found inside red blood cells. Although several normal and variant hemoglobin are known, the most common form, accounting for 95, 98%, is hemoglobin A.
When glucose circulates in the blood, some of it naturally binds to hemoglobin A. A molecule that combines glucose and hemoglobin is said to be glycated. The higher the blood glucose level, the more glycated hemoglobin is produced. Once glucose binds to the hemoglobin, it remains bound until the end of the lifespan of red blood cells which is normally 120 days. HbA1c test is used to diagnose, detect and monitor treatment of diabetes by assessing glucose levels over a period of time.
OptiBio is a South Korean in-vitro diagnostics (IVD) company focused in researching, developing, and manufacturing cutting edge fluorescence immunoassay (FIA) solutions to enhance and progress quality healthcare access globally. In 2020, OptiBio was selected by a research fund sponsored by the Bill Melinda Gates foundation for its unique and dedicated approach to immunoassay. OptiBio's fundamental approach of integrating in-house capabilities allows OptiBio to constantly improve its product performance, customize its solutions based on client feedback, develop new test parameters, and respond to changing market needs. OptiBio will continue to create, improve, and innovate world class diagnostic solutions in the field of
fluorescence immunoassay and point of care testing (POCT). Through this, we aim to ultimately transform medical diagnosis into a universally available right.